U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C15H13NO3.C4H11NO3
Molecular Weight 376.4044
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of KETOROLAC TROMETHAMINE

SMILES

c1ccc(cc1)C(=O)c2ccc3C(CCn32)C(=O)O.C(C(CO)(CO)N)O

InChI

InChIKey=BWHLPLXXIDYSNW-UHFFFAOYSA-N
InChI=1S/C15H13NO3.C4H11NO3/c17-14(10-4-2-1-3-5-10)13-7-6-12-11(15(18)19)8-9-16(12)13;5-4(1-6,2-7)3-8/h1-7,11H,8-9H2,(H,18,19);6-8H,1-3,5H2

HIDE SMILES / InChI
Ketorolac is a pyrrolizine carboxylic acid derivative structurally related to indomethacin. It is an NSAID and is used principally for its analgesic activity and has been shown to decrease opioid requirements in post-operative patients. It does not affect consciousness or respiration but does have effects on gastric mucosa, renal perfusion, and platelet function. Ketorolac tromethamine ophthalmic solution is sold under brand name acular LS and is indicated for the reduction of ocular pain and burning/stinging following corneal refractive surgery. Ketorolac tromethamine is a racemic mixture of [-]S- and [ ]R-enantiomeric forms, with the S-form having analgesic activity. Its antiinflammatory effects are believed to be due to inhibition of both cylooxygenase-1 (COX-1) and cylooxygenase-2 (COX-2) which leads to the inhibition of prostaglandin synthesis leading to decreased formation of precursors of prostaglandins and thromboxanes from arachidonic acid. The resultant reduction in prostaglandin synthesis and activity may be at least partially responsible for many of the adverse, as well as the therapeutic, effects of these medication. Analgesia is probably produced via a peripheral action in which blockade of pain impulse generation results from decreased prostaglandin activity.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
ACULAR LS

Approved Use

ACULAR LS ophthalmic solution is indicated for the reduction of ocular pain and burning/stinging following corneal refractive surgery.

Launch Date

1.05425279E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
2382.2 ng/mL
30 mg single, intramuscular
dose: 30 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
KETOROLAC plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
1805.8 ng/mL
31.5 mg single, nasal
dose: 31.5 mg
route of administration: Nasal
experiment type: SINGLE
co-administered:
KETOROLAC plasma
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
11152.8 ng × h/mL
30 mg single, intramuscular
dose: 30 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
KETOROLAC plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
7477.3 ng × h/mL
31.5 mg single, nasal
dose: 31.5 mg
route of administration: Nasal
experiment type: SINGLE
co-administered:
KETOROLAC plasma
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
4.8 h
30 mg single, intramuscular
dose: 30 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
KETOROLAC plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
5.24 h
31.5 mg single, nasal
dose: 31.5 mg
route of administration: Nasal
experiment type: SINGLE
co-administered:
KETOROLAC plasma
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
2 mg single, intrathecal
Highest studied dose
Dose: 2 mg
Route: intrathecal
Route: single
Dose: 2 mg
Sources:
healthy, 18-50
n = 5
Health Status: healthy
Age Group: 18-50
Sex: M+F
Population Size: 5
Sources:
30 mg single, intramuscular
Highest studied dose
Dose: 30 mg
Route: intramuscular
Route: single
Dose: 30 mg
Sources:
healthy, 19-45
n = 15
Health Status: healthy
Age Group: 19-45
Sex: M+F
Population Size: 15
Sources:
30 mg single, intranasal
Highest studied dose
Dose: 30 mg
Route: intranasal
Route: single
Dose: 30 mg
Sources:
healthy, 19-45
n = 15
Health Status: healthy
Age Group: 19-45
Sex: M+F
Population Size: 15
Sources:
31.5 mg 3 times / day multiple, intranasal
Recommended
Dose: 31.5 mg, 3 times / day
Route: intranasal
Route: multiple
Dose: 31.5 mg, 3 times / day
Sources:
unhealthy, 51.7
n = 199
Health Status: unhealthy
Condition: pain
Age Group: 51.7
Sex: M+F
Population Size: 199
Sources:
Other AEs: Nausea, Constipation...
Other AEs:
Nausea (58%)
Constipation (29%)
Vomiting (28%)
Nasal passage irritation (24%)
Headache (24%)
Flatulence (23%)
Anemia (19%)
Tachycardia (14%)
Pruritis (11%)
Dizziness (6%)
Sources:
90 mg single, intravenous
Dose: 90 mg
Route: intravenous
Route: single
Dose: 90 mg
Sources:
unhealthy
n = 8
Health Status: unhealthy
Condition: Percutaneous Nephrolithotomy operation
Population Size: 8
Sources:
Other AEs: Anaemia, Thrombocytopenia...
Other AEs:
Anaemia (below serious, 7 patients)
Thrombocytopenia (below serious, 3 patients)
Hyponatraemia (below serious, 3 patients)
Hypokalaemia (below serious, 2 patients)
Leucopenia (below serious, 1 patient)
Sources:
90 mg single, intravenous
Dose: 90 mg
Route: intravenous
Route: single
Dose: 90 mg
Sources:
unhealthy
n = 57
Health Status: unhealthy
Condition: Laparoscopic Donor Nephrectomy
Population Size: 57
Sources:
Other AEs: Hypercapnia, Thrombocytopenia...
Other AEs:
Hypercapnia (below serious, 12 patients)
Thrombocytopenia (below serious, 12 patients)
Leukocytosis (below serious, 38 patients)
Hypokalaemia (below serious, 20 patients)
Hyperkalaemia (below serious, 3 patients)
Hyponatraemia (below serious, 10 patients)
Sources:
AEs

AEs

AESignificanceDosePopulation
Pruritis 11%
31.5 mg 3 times / day multiple, intranasal
Recommended
Dose: 31.5 mg, 3 times / day
Route: intranasal
Route: multiple
Dose: 31.5 mg, 3 times / day
Sources:
unhealthy, 51.7
n = 199
Health Status: unhealthy
Condition: pain
Age Group: 51.7
Sex: M+F
Population Size: 199
Sources:
Tachycardia 14%
31.5 mg 3 times / day multiple, intranasal
Recommended
Dose: 31.5 mg, 3 times / day
Route: intranasal
Route: multiple
Dose: 31.5 mg, 3 times / day
Sources:
unhealthy, 51.7
n = 199
Health Status: unhealthy
Condition: pain
Age Group: 51.7
Sex: M+F
Population Size: 199
Sources:
Anemia 19%
31.5 mg 3 times / day multiple, intranasal
Recommended
Dose: 31.5 mg, 3 times / day
Route: intranasal
Route: multiple
Dose: 31.5 mg, 3 times / day
Sources:
unhealthy, 51.7
n = 199
Health Status: unhealthy
Condition: pain
Age Group: 51.7
Sex: M+F
Population Size: 199
Sources:
Flatulence 23%
31.5 mg 3 times / day multiple, intranasal
Recommended
Dose: 31.5 mg, 3 times / day
Route: intranasal
Route: multiple
Dose: 31.5 mg, 3 times / day
Sources:
unhealthy, 51.7
n = 199
Health Status: unhealthy
Condition: pain
Age Group: 51.7
Sex: M+F
Population Size: 199
Sources:
Headache 24%
31.5 mg 3 times / day multiple, intranasal
Recommended
Dose: 31.5 mg, 3 times / day
Route: intranasal
Route: multiple
Dose: 31.5 mg, 3 times / day
Sources:
unhealthy, 51.7
n = 199
Health Status: unhealthy
Condition: pain
Age Group: 51.7
Sex: M+F
Population Size: 199
Sources:
Nasal passage irritation 24%
31.5 mg 3 times / day multiple, intranasal
Recommended
Dose: 31.5 mg, 3 times / day
Route: intranasal
Route: multiple
Dose: 31.5 mg, 3 times / day
Sources:
unhealthy, 51.7
n = 199
Health Status: unhealthy
Condition: pain
Age Group: 51.7
Sex: M+F
Population Size: 199
Sources:
Vomiting 28%
31.5 mg 3 times / day multiple, intranasal
Recommended
Dose: 31.5 mg, 3 times / day
Route: intranasal
Route: multiple
Dose: 31.5 mg, 3 times / day
Sources:
unhealthy, 51.7
n = 199
Health Status: unhealthy
Condition: pain
Age Group: 51.7
Sex: M+F
Population Size: 199
Sources:
Constipation 29%
31.5 mg 3 times / day multiple, intranasal
Recommended
Dose: 31.5 mg, 3 times / day
Route: intranasal
Route: multiple
Dose: 31.5 mg, 3 times / day
Sources:
unhealthy, 51.7
n = 199
Health Status: unhealthy
Condition: pain
Age Group: 51.7
Sex: M+F
Population Size: 199
Sources:
Nausea 58%
31.5 mg 3 times / day multiple, intranasal
Recommended
Dose: 31.5 mg, 3 times / day
Route: intranasal
Route: multiple
Dose: 31.5 mg, 3 times / day
Sources:
unhealthy, 51.7
n = 199
Health Status: unhealthy
Condition: pain
Age Group: 51.7
Sex: M+F
Population Size: 199
Sources:
Dizziness 6%
31.5 mg 3 times / day multiple, intranasal
Recommended
Dose: 31.5 mg, 3 times / day
Route: intranasal
Route: multiple
Dose: 31.5 mg, 3 times / day
Sources:
unhealthy, 51.7
n = 199
Health Status: unhealthy
Condition: pain
Age Group: 51.7
Sex: M+F
Population Size: 199
Sources:
Leucopenia below serious, 1 patient
90 mg single, intravenous
Dose: 90 mg
Route: intravenous
Route: single
Dose: 90 mg
Sources:
unhealthy
n = 8
Health Status: unhealthy
Condition: Percutaneous Nephrolithotomy operation
Population Size: 8
Sources:
Hypokalaemia below serious, 2 patients
90 mg single, intravenous
Dose: 90 mg
Route: intravenous
Route: single
Dose: 90 mg
Sources:
unhealthy
n = 8
Health Status: unhealthy
Condition: Percutaneous Nephrolithotomy operation
Population Size: 8
Sources:
Hyponatraemia below serious, 3 patients
90 mg single, intravenous
Dose: 90 mg
Route: intravenous
Route: single
Dose: 90 mg
Sources:
unhealthy
n = 8
Health Status: unhealthy
Condition: Percutaneous Nephrolithotomy operation
Population Size: 8
Sources:
Thrombocytopenia below serious, 3 patients
90 mg single, intravenous
Dose: 90 mg
Route: intravenous
Route: single
Dose: 90 mg
Sources:
unhealthy
n = 8
Health Status: unhealthy
Condition: Percutaneous Nephrolithotomy operation
Population Size: 8
Sources:
Anaemia below serious, 7 patients
90 mg single, intravenous
Dose: 90 mg
Route: intravenous
Route: single
Dose: 90 mg
Sources:
unhealthy
n = 8
Health Status: unhealthy
Condition: Percutaneous Nephrolithotomy operation
Population Size: 8
Sources:
Hyponatraemia below serious, 10 patients
90 mg single, intravenous
Dose: 90 mg
Route: intravenous
Route: single
Dose: 90 mg
Sources:
unhealthy
n = 57
Health Status: unhealthy
Condition: Laparoscopic Donor Nephrectomy
Population Size: 57
Sources:
Hypercapnia below serious, 12 patients
90 mg single, intravenous
Dose: 90 mg
Route: intravenous
Route: single
Dose: 90 mg
Sources:
unhealthy
n = 57
Health Status: unhealthy
Condition: Laparoscopic Donor Nephrectomy
Population Size: 57
Sources:
Thrombocytopenia below serious, 12 patients
90 mg single, intravenous
Dose: 90 mg
Route: intravenous
Route: single
Dose: 90 mg
Sources:
unhealthy
n = 57
Health Status: unhealthy
Condition: Laparoscopic Donor Nephrectomy
Population Size: 57
Sources:
Hypokalaemia below serious, 20 patients
90 mg single, intravenous
Dose: 90 mg
Route: intravenous
Route: single
Dose: 90 mg
Sources:
unhealthy
n = 57
Health Status: unhealthy
Condition: Laparoscopic Donor Nephrectomy
Population Size: 57
Sources:
Hyperkalaemia below serious, 3 patients
90 mg single, intravenous
Dose: 90 mg
Route: intravenous
Route: single
Dose: 90 mg
Sources:
unhealthy
n = 57
Health Status: unhealthy
Condition: Laparoscopic Donor Nephrectomy
Population Size: 57
Sources:
Leukocytosis below serious, 38 patients
90 mg single, intravenous
Dose: 90 mg
Route: intravenous
Route: single
Dose: 90 mg
Sources:
unhealthy
n = 57
Health Status: unhealthy
Condition: Laparoscopic Donor Nephrectomy
Population Size: 57
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer




Drug as perpetrator​
PubMed

PubMed

TitleDatePubMed
Risks and benefits of nonsteroidal anti-inflammatory drugs in children: a comparison with paracetamol.
2001
Single-dose dipyrone for acute postoperative pain.
2001
Therapeutic uses of non-steroidal anti-inflammatory drugs in dentistry.
2001
Parecoxib (parecoxib sodium).
2001
Analgesic efficacy of ketorolac and morphine in neonatal rats.
2001 Apr
New advances in the treatment of sickle cell disease: focus on perioperative significance.
2001 Aug
Prohemorrhagic potential of dipyrone, ibuprofen, ketorolac, and aspirin: mechanisms associated with blood flow and erythrocyte deformability.
2001 Aug
Treatment of vinorelbine-associated tumor pain.
2001 Aug
Participation of the nitric oxide-cyclic GMP-ATP-sensitive K(+) channel pathway in the antinociceptive action of ketorolac.
2001 Aug 24
Chiral pharmacokinetics of ketorolac in sheep after intravenous and intramuscular administration of the racemate.
2001 Dec
[Aortic stent: the anesthesiologist's point of view].
2001 Dec
Delayed diffuse lamellar keratitis after laser in situ keratomileusis.
2001 Dec
Topical ketorolac after cataract surgery.
2001 Dec
A double-blind, randomized comparison of intramuscularly and intravenously administered parecoxib sodium versus ketorolac and placebo in a post-oral surgery pain model.
2001 Jul
Testing and comparison of non-opioid analgesics in amphibians.
2001 Jul
In vitro effects of NSAIDS and paracetamol on oxidative stress-related parameters of human erythrocytes.
2001 Jun
Effects of a non-steroidal (ketorolac tromethamine) and a steroidal (dexamethasone) anti-inflammatory drug on refractive state and ocular growth.
2001 Jun
Children's use of PCA following spinal fusion.
2001 Mar-Apr
Retrospective analysis of drug-induced urticaria and angioedema: a survey of 2287 patients.
2001 Nov
Opioid analgesics versus ketorolac in spine and joint procedures: impact on healthcare resources.
2001 Nov
Pain control after knee arthroplasty: intraarticular versus epidural anesthesia.
2001 Nov
The effect of ketorolac and sevoflurane anesthesia on renal glomerular and tubular function.
2001 Nov
Safety of ketorolac in the pediatric population after ureteroneocystostomy.
2001 Nov
Analgesia and COX-2 inhibition.
2001 Nov-Dec
Nonsteroidal anti-inflammatory drugs for perioperative pain control.
2001 Oct
Goal oriented general anesthesia for Cesarean section in a parturient with a large intracranial epidermoid cyst.
2001 Oct
Ketorolac vs tramadol in the treatment of postoperative pain during maxillofacial surgery.
2001 Sep
Upper gastrointestinal safety evaluation of parecoxib sodium, a new parenteral cyclooxygenase-2-specific inhibitor, compared with ketorolac, naproxen, and placebo.
2001 Sep
Can standard open pediatric urological procedures be performed on an outpatient basis?
2001 Sep
Effect of 10 pharmacologic probes on mRNA levels of inducible nitric oxide synthetase and selected inflammatory cytokines in a rat model of acute otitis media.
2002 Apr
Ketorolac, diclofenac, and ketoprofen are equally safe for pain relief after major surgery.
2002 Feb
Drug-induced extrapyramidal reactions.
2002 Feb
Is the administration of ketorolac associated with preemptive analgesia?
2002 Feb
Preemptive analgesic effect or short delay for inflammation?
2002 Feb
Upper GI mucosal effects of parecoxib sodium in healthy elderly subjects.
2002 Jan
A systematic review of adjuncts for intravenous regional anesthesia for surgical procedures.
2002 Jan
Epidural hematoma after outpatient epidural anesthesia.
2002 Jan
Opioid-free analgesia following total knee arthroplasty--a multimodal approach using continuous lumbar plexus (psoas compartment) block, acetaminophen, and ketorolac.
2002 Jan-Feb
Multimodal analgesia and intravenous nutrition preserves total body protein following major upper gastrointestinal surgery.
2002 Jan-Feb
Effect of ketorolac on renal function after donor nephrectomy.
2002 Jun
The influence of timing and route of administration of intravenous ketorolac on analgesia after hand surgery.
2002 Jun
Intra-muscular ketorolac administered as a supplemental analgesic for removal of impacted third molar teeth: a prospective study.
2002 Mar
Parenteral ketorolac and risk of myocardial infarction.
2002 Mar
Morphological and pharmacological evidence for the role of peripheral prostaglandins in the pathogenesis of neuropathic pain.
2002 Mar
Ketorolac for pain management after abdominal surgical procedures in infants.
2002 Mar
Ketorolac-based analgesia improves outcomes for living kidney donors.
2002 Mar 15
Comparison of the morphine-sparing effects of diclofenac sodium and ketorolac tromethamine after major orthopedic surgery.
2002 May
Protective role of cyclooxygenase (COX) inhibitors in burn-induced intestinal and liver damage.
2002 May
The role of spinal neuropeptides and prostaglandins in opioid physical dependence.
2002 May
Role for both spinal cord COX-1 and COX-2 in maintenance of mechanical hypersensitivity following peripheral nerve injury.
2002 May 24
Patents

Sample Use Guides

The recommended dose of ACULAR LS (ketorolac tromethamine ophthalmic solution) is one drop four times a day in the operated eye as needed for pain and burning/stinging for up to 4 days following corneal refractive surgery. Ketorolac tromethamine ophthalmic solution has been safely administered in conjunction with other ophthalmic medications such as antibiotics, beta blockers, carbonic anhydrase inhibitors, cycloplegics, and mydriatics.
Route of Administration: Other
It was discovered, that ketorolac inhibition of stretch-induced ureteral contractility was concentration-dependent between 1 nM and 1 microM. Local administration of ketorolac at these doses may be useful during the management of stones while at the same time limiting the risk for adverse effects. Porcine ureter strips attached to force displacement transducers were suspended in organ tissue baths that contained aerated Krebs buffer. Tissues equilibrated for 1 hour, and a spontaneous contractility rate was established. Tissues were incubated with a concentration-response curve of ketorolac (0.1 nM-10 microM) for 90 minutes and compared with indomethacin (1 muM) and dimethyl sulfoxide (DMSO) 0.1%. Contractility rates were recorded on a polygraph and analyzed for changes over exposure time
Name Type Language
KETOROLAC TROMETHAMINE
ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
USAN  
Official Name English
OMIDRIA COMPONENT KETOROLAC TROMETHAMINE
Brand Name English
(+/-)-5-BENZOYL-2,3-DIHYDRO-1H-PYRROLIZINE-1-CARBOXYLIC ACID, COMPOUND WITH 2-AMINO-2-(HYDROXYMETHYL)-1,3-PROPANEDIOL (1:1)
Common Name English
LIXIDOL
Brand Name English
KETOROLAC TROMETHAMINE [USP MONOGRAPH]
Common Name English
ACULAR
Brand Name English
KETOROLAC TROMETHAMINE COMPONENT OF OMIDRIA
Brand Name English
KETOROLAC TROMETAMOL
EP   MART.  
Common Name English
ACUVAIL
Brand Name English
TARASYN
Brand Name English
2-AMINO-2-(HYDROXYMETHYL)PROPANE-1,3-DIOL (1RS)-5-BENZOYL-2,3-DIHYDRO-1H-PYRROLIZINE-1-CARBOXYLATE
Systematic Name English
NSC-758637
Code English
KETOROLAC TROMETHAMINE [USP-RS]
Common Name English
1H-PYRROLIZINE-1-1H-PYRROLIZINE-1-CARBOXYLIC ACID, 5-BENZOYL-2,3-DIHYDRO, (+/-)-, COMPOUND WITH 2-AMINO-2-(HYDROXYMETHYL)-1,3-PROPANEDIOL (1:1)
Common Name English
KETOROLAC TROMETHAMINE [USAN]
Common Name English
DOLAC
Brand Name English
KETOROLAC (+/-)-FORM TROMETHAMINE SALT [MI]
Common Name English
KETOROLAC TROMETHAMINE [VANDF]
Common Name English
TORADOL
Brand Name English
KETOROLAC TROMETHAMINE [ORANGE BOOK]
Common Name English
SPRIX
Brand Name English
KETOROLAC TROMETAMOL [EP MONOGRAPH]
Common Name English
KETOROLAC TROMETAMOL [MART.]
Common Name English
KETOROLAC TROMETHAMINE [WHO-DD]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C1323
Created by admin on Fri Jun 25 21:05:05 UTC 2021 , Edited by admin on Fri Jun 25 21:05:05 UTC 2021
Code System Code Type Description
NCI_THESAURUS
C61798
Created by admin on Fri Jun 25 21:05:05 UTC 2021 , Edited by admin on Fri Jun 25 21:05:05 UTC 2021
PRIMARY
USP_CATALOG
1356665
Created by admin on Fri Jun 25 21:05:05 UTC 2021 , Edited by admin on Fri Jun 25 21:05:05 UTC 2021
PRIMARY USP-RS
EVMPD
SUB02835MIG
Created by admin on Fri Jun 25 21:05:05 UTC 2021 , Edited by admin on Fri Jun 25 21:05:05 UTC 2021
PRIMARY
PUBCHEM
84003
Created by admin on Fri Jun 25 21:05:05 UTC 2021 , Edited by admin on Fri Jun 25 21:05:05 UTC 2021
PRIMARY
FDA UNII
4EVE5946BQ
Created by admin on Fri Jun 25 21:05:05 UTC 2021 , Edited by admin on Fri Jun 25 21:05:05 UTC 2021
PRIMARY
ChEMBL
CHEMBL469
Created by admin on Fri Jun 25 21:05:05 UTC 2021 , Edited by admin on Fri Jun 25 21:05:05 UTC 2021
PRIMARY
EPA CompTox
74103-07-4
Created by admin on Fri Jun 25 21:05:05 UTC 2021 , Edited by admin on Fri Jun 25 21:05:05 UTC 2021
PRIMARY
DRUG BANK
DBSALT001045
Created by admin on Fri Jun 25 21:05:05 UTC 2021 , Edited by admin on Fri Jun 25 21:05:05 UTC 2021
PRIMARY
CAS
74103-07-4
Created by admin on Fri Jun 25 21:05:05 UTC 2021 , Edited by admin on Fri Jun 25 21:05:05 UTC 2021
PRIMARY
RXCUI
28200
Created by admin on Fri Jun 25 21:05:05 UTC 2021 , Edited by admin on Fri Jun 25 21:05:05 UTC 2021
PRIMARY RxNorm
MESH
D020911
Created by admin on Fri Jun 25 21:05:05 UTC 2021 , Edited by admin on Fri Jun 25 21:05:05 UTC 2021
PRIMARY
MERCK INDEX
M6623
Created by admin on Fri Jun 25 21:05:05 UTC 2021 , Edited by admin on Fri Jun 25 21:05:05 UTC 2021
PRIMARY Merck Index